Cargando…
An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy
Human papillomavirus (HPV) is the most common sexually transmitted agent worldwide. Early prevention with HPV vaccination is a safe and effective method against this disease. HPV vaccines provided more protection against several oncogenic HPV strains. Three prophylactic HPV vaccines have been approv...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828558/ https://www.ncbi.nlm.nih.gov/pubmed/35154080 http://dx.doi.org/10.3389/fimmu.2021.805695 |
_version_ | 1784647874085126144 |
---|---|
author | Yousefi, Zahra Aria, Hamid Ghaedrahmati, Farhoodeh Bakhtiari, Tahereh Azizi, Mahdieh Bastan, Reza Hosseini, Reza Eskandari, Nahid |
author_facet | Yousefi, Zahra Aria, Hamid Ghaedrahmati, Farhoodeh Bakhtiari, Tahereh Azizi, Mahdieh Bastan, Reza Hosseini, Reza Eskandari, Nahid |
author_sort | Yousefi, Zahra |
collection | PubMed |
description | Human papillomavirus (HPV) is the most common sexually transmitted agent worldwide. Early prevention with HPV vaccination is a safe and effective method against this disease. HPV vaccines provided more protection against several oncogenic HPV strains. Three prophylactic HPV vaccines have been approved to target high-risk HPV types and protect against HPV-related disorders. These existing vaccines are based on the recombinant DNA technology and purified L1 protein that is assembled to form HPV empty shells. The prophylactic vaccines are highly immunogenic and can induce production of specific neutralizing antibodies. However, therapeutic vaccines are different from these prophylactic vaccines. They induced cell-mediated immunity against transformed cells, instead of neutralizing antibodies. The second generation of prophylactic HPV vaccines, made from alternative viral components using cost-effective production strategies, is undergoing clinical evaluation. The purpose of this review is to provide a complete and up-to-date review of the types of HPV vaccines and the efficiency of each of them for readers. |
format | Online Article Text |
id | pubmed-8828558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88285582022-02-11 An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy Yousefi, Zahra Aria, Hamid Ghaedrahmati, Farhoodeh Bakhtiari, Tahereh Azizi, Mahdieh Bastan, Reza Hosseini, Reza Eskandari, Nahid Front Immunol Immunology Human papillomavirus (HPV) is the most common sexually transmitted agent worldwide. Early prevention with HPV vaccination is a safe and effective method against this disease. HPV vaccines provided more protection against several oncogenic HPV strains. Three prophylactic HPV vaccines have been approved to target high-risk HPV types and protect against HPV-related disorders. These existing vaccines are based on the recombinant DNA technology and purified L1 protein that is assembled to form HPV empty shells. The prophylactic vaccines are highly immunogenic and can induce production of specific neutralizing antibodies. However, therapeutic vaccines are different from these prophylactic vaccines. They induced cell-mediated immunity against transformed cells, instead of neutralizing antibodies. The second generation of prophylactic HPV vaccines, made from alternative viral components using cost-effective production strategies, is undergoing clinical evaluation. The purpose of this review is to provide a complete and up-to-date review of the types of HPV vaccines and the efficiency of each of them for readers. Frontiers Media S.A. 2022-01-27 /pmc/articles/PMC8828558/ /pubmed/35154080 http://dx.doi.org/10.3389/fimmu.2021.805695 Text en Copyright © 2022 Yousefi, Aria, Ghaedrahmati, Bakhtiari, Azizi, Bastan, Hosseini and Eskandari https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Yousefi, Zahra Aria, Hamid Ghaedrahmati, Farhoodeh Bakhtiari, Tahereh Azizi, Mahdieh Bastan, Reza Hosseini, Reza Eskandari, Nahid An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy |
title | An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy |
title_full | An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy |
title_fullStr | An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy |
title_full_unstemmed | An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy |
title_short | An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy |
title_sort | update on human papilloma virus vaccines: history, types, protection, and efficacy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828558/ https://www.ncbi.nlm.nih.gov/pubmed/35154080 http://dx.doi.org/10.3389/fimmu.2021.805695 |
work_keys_str_mv | AT yousefizahra anupdateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT ariahamid anupdateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT ghaedrahmatifarhoodeh anupdateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT bakhtiaritahereh anupdateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT azizimahdieh anupdateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT bastanreza anupdateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT hosseinireza anupdateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT eskandarinahid anupdateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT yousefizahra updateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT ariahamid updateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT ghaedrahmatifarhoodeh updateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT bakhtiaritahereh updateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT azizimahdieh updateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT bastanreza updateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT hosseinireza updateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy AT eskandarinahid updateonhumanpapillomavirusvaccineshistorytypesprotectionandefficacy |